- Clinical Trials
Genprex, Inc. CEO Rodney Varner tells Proactive the FDA has granted Fast Track Designation to the company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK)’s Keytruda in patients with stage III or IV non-small cell lung cancer (NSCLC), where disease progressed after treatment with Keytruda.
Our collaborators at the University of Pittsburgh showcased our novel, preclinical diabetes gene therapy at ADA2021. Watch this video by University of Pittsburgh Medical Center, sponsored by Genprex, to learn more about this gene therapy approach for the treatment of both Type 1 and Type 2 diabetes.
The event, titled, “Advances in Gene Therapy for Oncology: New Opportunities with REQORSA™ (TUSC2),” was moderated by James Molloy, Managing Director, Equity Research at AGP and featured discussions on Genprex’s novel immunogene therapy for lung cancer, with experts Andrew Becker, M.D., Ph.D. and COL (ret) George Peoples, M.D., FACS. This event was recorded on April 27, 2021. Since the recording, Genprex has initiated its Acclaim-1 clinical trial and has made modifications to its Acclaim-2 protocol.
Noble Capital Markets’ Senior Research Analyst, Robert LeBoyer, sits down with Genprex President & CEO, Rodney Varner, for this exclusive interview. Recorded on April 22, 2021.
Genprex CEO, Rodney Varner, tells Proactive its collaborators have presented positive preclinical data for the combination of REQORSA in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC), as well as for REQORSA in combination with targeted therapies.
Varner says the data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The positive data is helpful for Genprex’s plan to launch a pair of upcoming clinical trials.
Rodney Varner, President and CEO of Genprex, joins CEO Roadshow’s Mike Elliott to talk about the company’s gene therapies for cancer and diabetes.
The triple combination of chemotherapy, immunotherapy (immune checkpoint blockade) and REQORSA demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models.
Dr. George Gittes, the inventor of the diabetes gene therapy, GPX-002, discusses paradigm shifts in diabetes and pediatric medicine with Progress, Potential, and Possibilities’ Ira S. Pastor.
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive it has met the necessary specifications and passed the final release tests for its first manufacturing run of REQORSA immunogene therapy in advance of non-small cell lung cancer (NSCLC) clinical trials.
Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based group has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrisso and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC).